A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate, Trial ID 5094-CL-0102

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of multiple ascending intravenous doses of ASP5094 in male and female subjects with rheumatoid arthritis (RA) on methotrexate (MTX).

Additional Study Details

Phase

Product

N/A

Product

ASP5094

Placebo

Type

Interventional

Masking

Double (Participant, Investigator)

Enrollment number

Show Additional Study Details

Study documents

Scientific Results Summary

Available Language(s): English

Download Document(s)

Plain Language Summary

Available Language(s): English

Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate? Contact us by filling out your information to the right and we’ll respond to you.

Requestor Information [I am…]

A caregiver
A healthcare provider
A parent
A patient
A patient advocate

First name

Last Name

Country/Region

Algeria
Argentina
Armenia
Australia
Austria
Belarus
Belgium
Bosnia And Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Dominican Republic
Egypt
Estonia
Finland
Former Serbia and Montenegro
France
Georgia
Germany
Greece
Guatemala
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Latvia
Lebanon
Lithuania
Macedonia
Malaysia
Mexico
Montenegro
Morocco
Netherlands
New Zealand
Norway
Panama
Peru
Philippines
Poland
Portugal
Puerto Rico
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan, Province of China
Thailand
Turkey
Ukraine
United Kingdom
United States
Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

I give my consent to the processing of my personal data mentioned above according to Astellas Privacy Notice & Cookies Policy

Locations

Withdrawn

Site PL48004

Nowa Sol, Poland, 67-100

Completed

Site US10008

Debary, FL, United States, 32713-1818

Completed

Site US10002

Anniston, AL, United States, 36207

Completed

Site US10004

Jacksonville, FL, United States, 32216

Completed

Site US10010

Memphis, TN, United States, 38119

Completed

Site PL48003

Warszawa, Poland, 00-660

Completed

Site PL48007

Stalowa Wola, Poland

Completed

Site PL48006

Lodz, Poland, 91-347

Completed

Site PL48011

Krakow, Poland, 31-637

Withdrawn

Site PL48001

Lublin, Poland, 20-582

Completed

Site US10001

Dallas, TX, United States, 75231

Completed

Site US10003

Duncansville, PA, United States, 16635

Completed

Site PL48009

Elblag, Poland, 82-300

Completed

Site PL48008

Wroclaw, Poland, 50-556

Completed

Site US10009

Miami Lakes, FL, United States, 33014

Trial info

Follow Trial

Age

18 - 65 years

Condition

Rheumatoid Arthritis

Sex

Female & Male

Trial Dates

Feb 2016 - Sep 2017

Share with

Additional Study Details

Inclusion Criteria

Subject has a body mass index (BMI) of ≤ 35 kg/m2, inclusive, and must weigh at least 50 kg at screening.
Subject has absolute neutrophil count within normal limits at screening. The assessment may be repeated once during screening.
Subject has RA that was diagnosed according to the 1987 revised criteria of the American College of Rheumatology (ACR) ≥ 6 months prior to screening.
Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class I, II or III at screening.
Subject MUST be on concomitant MTX:
- for ≥ 3 months prior to day 1, and
- at a stable dose (10 25 mg/week) for ≥ 28 days prior to day 1 and throughout the study.
Subject’s other medications taken for the treatment of RA at the time of screening must meet the noted stability requirements and remain on a stable regimen, as follows:
- Nonsteroidal antiinflammatory drugs (NSAIDs), selective cyclooxygenase-2 (COX- 2) inhibitors, oral corticosteroids (≤ 10 mg of prednisone, or equivalent, daily) or low dose opioids (≤ 30 mg of oral morphine, or equivalent, daily) must be stable for ≥ 28 days prior to screening,
- Hydroxychloroquine (Plaquenil®) and sulfasalazine (e.g., Azulfidine®) must have started ≥ 2 months, and be stable for ≥ 28 days, prior to day 1.
Female subject must be either:
- Of nonchildbearing potential: postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile
- Or, if of childbearing potential, Agree not to try to become pregnant during the study and for 60 days after the final study drug administration; must have a negative urine pregnancy test at screening and day 1, And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control† (at least 1 of which must be a barrier method) starting at screening and throughout the study period and for 60 days after the final study drug administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days.
Female subject must not donate ova starting at screening and throughout the study period, and for 60 days after the final study drug administration.
Male subject and his female spouse/partner who is of childbearing potential must be using highly effective forms of contraception consisting of 2 forms of birth control† (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 60 days after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period, and for 60 days after the final study drug administration
Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria

Subject has an ongoing clinically significant systemic disease such as uncompensated heart failure, uncontrolled diabetes mellitus, severe hepatic failure, severe pulmonary disease or inflammatory bowel disease.
Subject has a history of any malignancy in the past 5 years, except for adequately-treated, nonmelanoma skin cancer and adequately-treated in-situ cervical cancer.
Subject has a history of severe allergic or anaphylactic reactions to drugs.
Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/ substance abuse within past 6 months prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).
Subject has an ongoing infection or has had an infection requiring intravenous antibiotics within 1 month prior to day 1.
Subject has a known history of a positive test for human immunodeficiency virus (HIV) antibody.
Subject has a past history of serious opportunistic infection.
Subject has a positive QuantiFERON-TB Gold test within 90 days of, or at screening, and has not completed an adequate course of antimicrobial therapy per Centers for Disease Control or local guidelines.
Subject’s laboratory test results at screening or prior to study drug dosing on day 1:
- Outside the normal limits and considered by the investigator to be clinically significant with regard to the remaining per-protocol laboratory tests, and/or
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) are > 2 times the upper limit of normal.
Subject received any live or live-attenuated vaccine within 30 days prior to day 1.
Subject received any of the following:
- Oral or injectable gold, azathioprine, penicillamine, cyclosporine, tacrolimus or tofacitinib (Xeljanz®) within 30 days prior to day 1.
- Anakinra (Kineret®), etanercept (Enbrel®), adalimumab (Humira®), tocilizumab (Actemra®), infliximab (Remicade®), or golimumab (Simponi®) within 60 days prior to day 1.
- Leflunomide (Arava®) within 60 days prior to day 1, unless the subject has undergone cholestyramine washout at least 30 days prior to day 1.
- Certolizumab (Cimzia®) and abatacept (Orencia®) within 90 days prior to day 1.
- Rituximab (Rituxan®) or any other antiCD20 antibody, and cyclophosphamide within 180 days prior to day 1.
- Treatment with any other conventional disease modifying antirheumatic drugs (DMARDs), or treatment with any other biologics not previously noted within 28 days or 5 half-lives, whichever is longer, prior to day 1.
Subject has participated in a previous clinical study with treatment with ASP5094 or has participated in another dose cohort of the current trial.
Subject has previously received an experimental agent within 28 days or 5 half-lives, whichever is longer, prior to day 1.
Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to day 1.
Subject had surgery or has a planned elective surgery (including oral surgery) within 1 month prior to screening and 3 months after last study drug administration.
Subject has a wound that is currently healing.
Subject has any other condition, which in the opinion of the investigator, precludes the subject’s participation in the trial.
Subject is an employee of the Astellas group or vendors involved in the study.

Frequently Asked Questions

Are clinical trials only for people with advanced cancer?

While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

Will I have to stop my current treatment to participate in a clinical trial?

Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

Should I be worried about getting a placebo?

In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

Do I need a referral from my doctor to take part in a study?

Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

Explore More

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Study summary

Additional Study Details

Study documents

Get more information

Locations

Frequently Asked Questions

Explore More

What are clinical trials?

Why are Clinical Trials Important?

Why Participate in a Clinical Trial?